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1668 The Journal of Thoracic and CardObjective: We designed this study to evaluate the early hemodynamic performance
of the recently introduced Carpentier-Edwards PERIMOUNT Magna bioprosthesis
(Edwards Lifesciences, Irvine, Calif) and compare it with those of the conventional
Carpentier-Edwards PERIMOUNT stented bioprosthesis (Edwards Lifesciences)
and Edwards Prima Plus porcine stentless bioprosthesis (Edwards Lifesciences).
Methods: Sixty-three patients (70 years old) were enrolled in this prospective,
randomized study. At operation, once the annulus had been measured, the best size
suitable was assessed for each of the three valves before random assignment.
Transthoracic echocardiography was performed before discharge to evaluate early
postoperative hemodynamic performances of the different valves implanted.
Results: The best size suitable of Edwards Prima Plus (24.3  1.7 mm) was
significantly superior to those of both the Carpentier-Edwards PERIMOUNT Magna
(23.4 2.1 mm) and Carpentier-Edwards PERIMOUNT (22.4 1.8 mm). The best
size suitable of the Carpentier-Edwards PERIMOUNT Magna, however, was sig-
nificantly superior to that of the Carpentier-Edwards PERIMOUNT. Furthermore
the best size suitable of the Carpentier-Edwards PERIMOUNT Magna was equal to
the measured annulus in 55% of patients, as opposed to 25% for the Carpentier-
Edwards PERIMOUNT (P  .001). Mean implanted labeled size of the Edwards
Prima Plus was significantly higher than those of both the Carpentier-Edwards
PERIMOUNT Magna and the Carpentier-Edwards PERIMOUNT (24.6  1.9 mm,
23.1  1.9 mm, and 22.5  1.8 mm, respectively). Early postoperative hemody-
namic performance of the Carpentier-Edwards PERIMOUNT Magna, however, was
superior to those of both the Edwards Prima Plus and the Carpentier-Edwards
PERIMOUNT in both effective orifice area index (1.07  0.4 cm2/m2, 0.87  0.3
cm2/m2, and 0.80  0.2 cm2/m2, respectively) and mean peak gradient (20 6 mm Hg,
27  8 mm Hg, and 28  12 mm Hg, respectively).
Conclusion: The improved design of the recently introduced third-generation stented
bioprosthesis Carpentier-Edwards PERIMOUNT Magna allows implantation of a
significantly bigger valve than with the old generation. Furthermore, the improved
hemodynamic performance of the Carpentier-Edwards PERIMOUNT Magna com-
pares favorably with both the Carpentier-Edwards PERIMOUNT and the Edwards
Prima Plus.
There is general agreement that a bioprosthesis should be the prosthesis ofchoice for aortic valve replacement (AVR) in the elderly population; how-ever, debates are ongoing regarding which type of bioprosthesis should be
preferred. Since their introduction in the late 1980s,1 stentless bioprostheses have
been proposed as the best choice for AVR in elderly patients to improve post-
operative hemodynamic performance and reduce the risk of patient-prosthesis
mismatch.2,3 Several studies have tried to elucidate benefits of stentless valves
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CDrelative to stented bioprostheses, and contrasting results
have been reported so far. Recent randomized studies4,5
have failed to confirm significant benefits of stentless valves
previously reported from nonrandomized studies.6-13 Fur-
thermore, a new generation of stented bioprosthesis has
been recently introduced with claims of improved hemody-
namic performance. We designed this study to evaluate the
early hemodynamic performance of the recently introduced
Carpentier-Edwards PERIMOUNT Magna stented biopros-
thesis (PEM; Edwards Lifesciences, Irvine, Calif) and com-
pare it with those of two frequently used bioprostheses, the
conventional Carpentier-Edwards PERIMOUNT stented
bioprosthesis (CEP; Edwards Lifesciences) and the Ed-
wards Prima Plus stentless porcine bioprosthesis (PPS; Ed-
wards Lifesciences). We decided to compare different pros-
theses from the some company to reduce the bias related to
different ratios between labeled size and internal diameter
seen when comparing different bioprosthesis from different
companies.14
Patients and Methods
Sixty-three patients (70 years old) requiring AVR were enrolled
at our institution into this prospective, randomized study during a
period of 18 months. Patients requiring urgent or additional sur-
gical procedures other then coronary artery bypass grafting were
excluded from the study, along with those with poor left ventric-
ular function (ejection fraction 30%).
Study Design
The study was approved by the local ethics committee. After
written, informed consent was provided, patients matching the
inclusion criteria were enrolled in the study. Specific anatomic
contraindications to stentless valve implantation (eg, excessive
aortic calcifications, bicuspid native aortic valve, coronary anom-
alies) were evaluated during the operation. In the presence of
specific contraindications, the patient was withdrawn from the
study.
After excision of the native valve, the annulus was thoroughly
decalcified and measured with a universal (Hegar) sizer. Once the
best size suitable had been assessed for each of the three valves,
Abbreviations and Acronyms
AVR aortic valve replacement
CEP  Carpentier-Edwards PERIMOUNT stented
bioprosthesis
EOA  effective orifice area
LVM left ventricular mass
PEM  Carpentier-Edwards PERIMOUNT Magna
stented bioprosthesis
PPS  Edwards Prima Plus stentless porcine
bioprosthesisrandom assignment was disclosed.
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The CEP (bovine pericardial stented bioprosthesis) and PPS (por-
cine stentless bioprosthesis) are well-known prostheses exten-
sively described in previous studies.15-19 The PEM is a newer
generation bovine pericardial stented bioprosthesis recently intro-
duced to the market. It is characterized by a new supra-annular
design that is claimed to have better hemodynamic and flow
characteristics. The recently Food and Drug Administration–
approved original ThermaFix decalcification process (Edwards
Lifesciences) is also expected to improve the long-term durability.
Surgical Technique
All operations were carried out through a standard midline ster-
notomy with cardiopulmonary bypass (after standard ascending
aorta and right atrium cannulation) with moderate hypothermia
(32°C). Myocardial protection was obtained in all cases with an
initial infusion of cold blood cardioplegia, with additional main-
tenance doses every 15 to 20 minutes.
The selected valve was implanted according two different
techniques. PPSs were implanted with a standard subcoronary
technique with a 120° rotation of the valve. Interrupted single
sutures of unpledgetted 4-0 polyester (Ethibond; Ethicon, Inc,
Somerville, NJ) were used for the inflow, and running 4-0 polypro-
pylene sutures (Prolene; Ethicon) were used for the outflow. Both
CEP and PEM bioprostheses were implanted in the supra-annular
position with interrupted, radial, noneverting, unpledget-supported
2-0 polyester sutures (Ethibond; Ethicon, or Ti-Cron [Sherwood-
Davis & Geck, St Louis, Mo]).
Postoperative Evaluation
Hemodynamic performance of each valve implanted was evalu-
ated before patient discharge with transthoracic echocardiography
performed by a senior technician who was blinded to the type of
prosthesis used. Effective orifice area (EOA), peak and mean
pressure gradients, left ventricular ejection fraction, and cardiac
output were calculated according to standard formulas previously
published.5,15,16
Statistical Analysis
Data are reported as mean  SD. Normal distribution was tested by
Kolmogorov-Smirnov test. Categoric data were compared with either
the 2 or Fisher exact test, with Yates correction applied when
appropriate. Continuous variables were compared by analysis of vari-
ance. Correlation between increasing size and improved EOA was
established by linear regression model. SPSS application software
version 11.5 (SPSS Inc, Chicago, Ill) was used for statistical analysis.
Results
Of 63 patients enrolled, 3 were withdrawn before random
assignment because of specific contraindications to stentless
valve implantation. Preoperative characteristics of the 60
patients who entered the randomization are summarized in
Table 1. Although the difference in body surface area ap-
proached statistical significance, the intraoperative annulus
measurements did not differ among the three groups (24.2
 1.7 mm, 23.9  1.6 mm, and 24.3  1.9 mm for PEM,
CEP, and PPS, respectively). As far as the specific valve
and Cardiovascular Surgery ● Volume 130, Number 6 1669
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CDsizing was concerned (Table 2), PPS had a better best size
suitable than did either of the two stented bioprosthesis. The
best size suitable of the PEM, however, was significantly
better than that of CEP. Furthermore, looking at the best
size suitable and annular measurement, we found in the
PEM group a significantly larger percentage of patients with
a best size suitable equal to the annular measurement than in
the CEP group. The mean implanted size of the prosthesis
reflected the differences of the best size suitable. As shown
in Table 3, mean size of implanted PPS (24.6  1.9 mm)
was significantly superior to those of both PEM (23.1 1.9
mm) and CEP (22.5  1.8 mm). The difference between
PEM and CEP failed to reached statistical significance;
however, the percentage of patients receiving a PEM of the
same size of the annulus (50%) was significantly higher
than in the CEP group (15%). With respect to operative
parameters, PPS relative to PEM and CEP required signif-
icantly prolonged cardiopulmonary bypass time (161  44
minutes, 116  44 minutes, and 93  36 minutes, respec-
tively) and aortic crossclamp time (111 29 minutes, 80
30 minutes, and 67 27 minutes, respectively). One patient
(PPS group) died within 30 days of the operation (cumula-
tive 30-day mortality 1.6%), and 1 patient (CEP group)
required hemofiltration. Postoperative hemodynamic perfor-
mances were obtained from 56 patients, because the deceased






Age (y, mean  SD) 73
Body surface area (m2, mean SD) 1.78
Aortic valve area (cm2, mean SD) 0.63
Transaortic gradient (mm Hg, mean  SD)
Peak 101
Mean 59
Left ventricular ejection fraction (%, mean  SD) 59%
AVR plus coronary artery bypass grafting (No.) 10
TABLE 2. Best size suitable evaluation: Comparison of an
in all patients
P
Annulus (mm, mean  SD) 24.1
Best size suitable (mm, mean  SD) 23.4
Relationship of best size suitable to annulus (No.)
Same size 33
Undersized 27
Oversized 0*PPS versus PEM, PPS versus CEP, and PEM versus CEP.
1670 The Journal of Thoracic and Cardiovascular Surgery ● Decpatient and 3 patients (1 each group) in atrial fibrillation at the
time of discharge were not considered. Mean postoperative
EOA and EOA index of patients receiving PEM compared
favorably with those of patients receiving both CEP and
PPS (Table 4). Furthermore, patient-prosthesis mismatch
(according to the definition of patient-prosthesis mismatch
as EOA index 0.85 cm2/m2) was less likely with PEM.
The peak transvalvular gradient of PEM was also signifi-
cantly reduced relative to CEP and PPS, whereas mean
gradient did not differ significantly among the three valves.
Although a complete size-by-size analysis of the hemody-
namic performance for each valve was not possible because
of the limited number of patients in each group, a significant
correlation was seen between increasing valve size and
improved EOA for PEM but not for PPS (the latter value,
however, did approach statistical significance) or CEP (Fig-
ure 1). Finally, the ratio between postoperative in vivo EOA
and in vitro EOA for any given size was significantly better
for PEM than for both CEP and PPS (0.92  0.09, 0.81 
0.11, and 0.82  0.09, respectively, P  .05 for PEM vs
CEP and PEM vs PPS).
Discussion
The valve of choice for AVR in the elderly population is
still under discussion. First-generation stented bioprosthe-
CEP PPS P value
20 20
.717
) 9 (45%) 7 (35%)
) 11 (55%) 13 (65%)
74  4 73  5 .382
19 1.86 0.2 1.71 0.2 .07
3 0.65 0.2 0.62 0.2 .713
100 20 103 21 .706
60 16 58 10 .768
% 60% 7% 59% 15% .865
) 5 (25%) 11 (55%) .122
measurement and best size suitable for the three valves
CEP PPS P value*
.8 24.1 1.8 24.1 1.8
.1 22.4 1.8 24.3 1.7 .0001
.0001
) 10 (25%) 58 (96%)
) 50 (75%) 0 (0%)
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CDsis, introduced in 1965,20 have provided satisfactory clinical
results but limited durability21,22 and suboptimal hemody-
namic performance in specific settings (small aortic annu-
lus). To overcome some of these problems, stentless bio-
prosthesis were introduced in the late 1980s1 and have been
considered by many authors the prosthesis of choice even if
a more demanding technique of implantation is necessary.2,3
Despite several published studies comparing the early and
long-term results of patients receiving stented versus stent-
less bioprostheses, a clear and unanimous identification of
the prosthesis of choice has not yet been reached. Implan-
tation of a bigger size prosthesis,6 better hemodynamic
performance either at rest or during maximal exercise,7,8
and improved left ventricular mass (LVM) regression9,10
have been shown in nonrandomized trials after stentless
valve implantation. Furthermore, improved postoperative
survival was reported by David and colleagues11 and then
confirmed by Westaby and associates12 and Luciani and
colleagues.13 Recent randomized studies by Doss and co-
workers4 and Cohen and associates,5 however, have yielded
TABLE 3. Comparison of annular measurement and size of
valve implanted (n  20 patients per group)
PEM CEP PPS P value
Size implanted per
label
Mean  SD 23.1 1.9 22.5 1.8 24.6 1.9 .002*
Median 23 21 25






Same size 10 (50%) 3 (15%) 19 (95%)
Undersized 10 (50%) 17 (85%) 0 (0%)
Oversized 0 (0%) 0 (0%) 1 (5%)
*PPS versus CEP and PPS versus PEM. †PPS versus PEM, PPS versus
CEP, and PEM versus CEP.
TABLE 4. Early postoperative hemodynamic performance a
P
Patients (No.)
EOA (cm2, mean  SD) 1.92
EOA index† (cm2/m2, mean  SD) 1.07
Patient-prosthesis mismatch (No., EOA index
0.85 cm2/m2)
3 (
Transaortic gradient (mm Hg, mean  SD)
Peak 20
Mean 10
Left ventricular ejection fraction (%, mean  SD) 57*PEM versus CEP. †Ratio of EOA to body surface area. ‡PEM versus CEP and
The Journal of Thoraciccontrasting results showing no significant differences in
terms of hemodynamic performance and LVM regression.
The introduction of newer generation stented bioprosthe-
sis with claims of improved hemodynamic performance has
added fuel to the current controversies.10 The aim of our
study was to evaluate the early hemodynamic performance
of the third-generation PEM with a specific supra-annular
design and a new decalcification treatment. We decided to
compare its performance with those of the previous gener-
ation of the same valve (CEP) and the porcine stentless
valve made by the same company (PPS). The CEP has been
used for more than 15 years, and its excellent hemodynamic
performances and long-term clinical results have been
clearly reported.15,16 The PPS is a stentless porcine valve
introduced in the early 1990s. Despite preliminary results
reporting controversial performance,17,18 recent studies have
confirmed good medium-term hemodynamic and clinical re-
sults.19 In fact, as previously reported for other stentless
valves,23,24 the performance of the PPS appears to signifi-
cantly improve after the first year.
aluated by transthoracic echocardiography (n  54)
CEP PPS P value
19 18
8 1.48 0.8 1.47 0.4 .087
4 0.80 0.2 0.87 0.3 .028*
9 (47%) 5 (27%) .102
28 12 27 8 .017*‡
13 6 12 4 .153
56 11 59 11 .733
Figure 1. Linear regression analysis: labeled size of valve bio-
prosthesis versus EOA (PEM r  0.54, P < .05; CEP r  0.25, P >








 13PEM versus PPS.
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allows a larger stented bioprosthesis to be implanted; in fact,
50% of patients received a valve the same size as the
annulus, versus 15% in the CEP group. Despite the previ-
ously reported difficulties in comparing labeled size be-
tween different bioprostheses,14 this finding is certainly
important because these two valves have the same internal
diameter for a given labeled size.
The analysis of the early postoperative performance
shows a second important finding: the early hemodynamic
performance of PEM compared favorably with those of the
other two valves in this study. Values in our study of early
postoperative EOA and peak transvalvular gradient for CEP
and PPS were similar to those reported in previous stud-
ies,10,14-16,25 (although Doss and coworkers4 recently re-
ported better hemodynamic parameters for CEP); thus the
performance of the PEM appears really encouraging. Al-
though the accuracy of echocardiographically calculated
EOA has been continually questioned since its introduction
in the early 1990s,26 it and EOA index remain the param-
eters most frequently used to evaluate the efficacy of a valve
bioprosthesis and seem to be the only useful way to define
patient-prosthesis mismatch. The small number of patients
in each group made a size-by-size statistical analysis diffi-
cult; however, the statistically significant correlation be-
tween increasing size and improved EOA for PEM seems to
indicate that the benefits of PEM are not limited to small
valves. With respect to the incidence of patient-prosthesis
mismatch (according to the accepted definition of patient-
prosthesis mismatch as EOA index 0.85 cm2/m2), PEM
seems to allow further benefits relative to CEP. In our
experience, the incidence of patient-prosthesis mismatch
after CEP implantation was slightly high; however, a sim-
ilar tendency has been previously reported by Jamieson and
associates.25 Furthermore, we should also consider that the
mean body surface area in our series was superior to figures
reported in other studies, thus affecting the estimation of
postoperative patients-prosthesis mismatch. Finally, the
benefit of the innovative design of the PEM is also demon-
strated by its significantly superior ratio between postoper-
ative in vivo EOA and in vitro EOA published by the
company. A good correlation between in vivo and in vitro
EOA has been previously shown, although the in vivo value
is generally less than the in vitro value.27 In our series, the
ratio in vivo to in vitro EOA was significantly superior for
PEM relative to CEP. Considering that CEP had previously
shown superior in vitro performance relative to other
stented bioprostheses,28 we speculate that the design of the
PEM allows a more complete and physiologic use of the
valve area. In our series, early postoperative hemodynamic
performance of the PEM also compared favorably with that
of the PPS; however, determination of a real difference
between PEM and PPS requires further clarification with a
1672 The Journal of Thoracic and Cardiovascular Surgery ● Declong-term control because of the proven improved perfor-
mance of PPS after the first year after implantation.18,19
In conclusion, our study confirmed good early postoper-
ative hemodynamic performance for CEP and PPS but also
demonstrated the innovative design and clear advantage of
PEM relative to the previous generation CEP. We believe
that the differences seen in this study favor the PEM sig-
nificantly and should be considered carefully when choos-
ing a bioprosthesis for AVR in an elderly patient, especially
one with a small annulus. Long term-results, however, are
required to clarify whether the improved early hemody-
namic performance of this newer generation stented bio-
prosthesis will allow regression of LVM comparable to
those obtained after implantation of a stentless valve.
Study Limitations
The limited number of patients in each group did not allow
a complete size-by-size analysis of hemodynamic perfor-
mance for the different valves. Furthermore, the study fo-
cused on early postoperative hemodynamic performance,
and the impact of the previously demonstrated late improve-
ment in hemodynamic performance of stentless valves has
therefore not been evaluated. For the same reason, we could
not analyze the effect of the improved hemodynamic per-
formance on LVM regression.
We thank Sabino Scolletta, MD, from Department of Cardio-
thoracic Surgery and Biomedical Science at University Hospital of
Siena, Siena, Italy, for the statistical analysis.
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Discussion
Dr Neal Kon (Winston-Salem, NC). I congratulate Totaro and
colleagues on this randomized, prospective trial of three differ-
ent tissue bioprostheses. They concluded that the new PEM
The Journal of Thoracicvalve is the prosthesis of choice in the elderly population on the
basis of differences in discharge gradients and EOAs. The new
PEM valve has a less bulky stent by 2 mm than the older CEP
valve and does not have a portion of the valve prosthesis that
protrudes into the left ventricular outflow tract. This appears to
allow implantation of a larger valve in the same size aortic
annulus.
With regard to the stentless counterpart, PPS, when an even
larger valve could be implanted in the same size annulus, the
gradients were even higher and the EOAs were even smaller. Let
me address why I believe the stentless valve was treated unfairly
in this study, which resulted in stentless gradients higher than seen
in other published studies.
As mentioned in the article, one of the limitations of this study
is that the only hemodynamic parameters measured were measured
at the time of discharge from the hospital, early after the operation.
It is well documented in the literature that the early hemodynamics
of a stentless valve should be evaluated at the 3- to 6-month
interval, because the gradients drop significantly during this time
frame when using a subcoronary technique.
Also, relative to the annulus size, the study used larger size
stentless valves with a subcoronary technique. This too can lead to
higher gradients, because you may simply be stuffing more tissue
inside the same size aortic root. It is analogous to using a bulkier
stent.
A root replacement technique for the stentless valve—as is
used with homograft valves, autograft valves, and some stentless
valves—would, I believe, result in less turbulent flow, lower
gradients, and larger EOAs. The result with the root technique
would be hemodynamics comparable to those in people without
any valvular heart disease at all, and that particular approach
would be worthwhile for the patient with a small aortic annulus.
Mr Totaro, there is fear among many surgeons of placing a
larger stented valve in the same size annulus. In particular, they
fear tearing the aortic root, difficulty seating the valve, obstructing
low lying coronary ostia, and distortion of the bioprosthesis, pos-
sibly producing some aortic insufficiency. There were no data in
the presentation or article about aortic insufficiency. Can you give
us some indication of the incidence of aortic insufficiency in your
study and some technical tips that you use in seating a larger
stented valve in the same size annulus? And what do you recom-
mend regarding a supra-annular implantation technique in patients
who have low-lying coronary arteries?
Finally, knowing the specific drawbacks of evaluating a stent-
less valve with just discharge echocardiographic data, do you
really think you can make stentless valve comparisons in this
particular study?
Mr Totaro. Professor Kon, it is a privilege for us to have
you as primary discussant. I would like to thank you for your
kind comments and interesting questions.
With respect to your first comment about the unfair treatment
received by the stentless valve in this study, I stressed in the
presentation that the lack of medium-term follow-up is one of the
limitations of this study. We are aware that performance of the
stentless valve improves after 6 to 12 months from implantation
and, therefore, the conclusion of our study places more stress on
the differences between the PEM and the CEP than on differences
with the stentless valve.
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CDAs far as your comment on the technique of implantation used
for the stentless valve, we definitely share your concern about
oversizing stentless valves with a subcoronary technique; there-
fore, we only oversized the valve in 1 patient with a large sinotu-
bular junction.
We are also aware of the potential benefit of the mini-root
technique compared with subcoronary implantation, but we de-
cided to use the technique more frequently reported in the litera-1674 The Journal of Thoracic and Cardiovascular Surgery ● DecWe did not experience postoperative aortic insufficiency
(other than trivial). With respect to oversizing stented valves,
once more we share your concern. We purposely did not over-
size the valve in any of the patients and the smallest valve
implanted was 21 mm. This was possibly due to the surgical
technique used (radial single unpledgetted suture) that avoids
any purse-string effect.
Finally, we are planning to continue the study and to present the
ture for this valve. comparison of hemodynamic performance at medium-term results.ember 2005
